QBiotics Announces Clinical Collaboration with MSD Targeting Unresectable Melanoma
– MSD collaboration to investigate QBiotics’ lead molecule tigilanol tiglate in combination with KEYTRUDA(R) (pembrolizumab) – Tigilanol tiglate is a
Read More
– MSD collaboration to investigate QBiotics’ lead molecule tigilanol tiglate in combination with KEYTRUDA(R) (pembrolizumab) – Tigilanol tiglate is a
Read More